Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis.

ABSTRACT: Patient-derived xenografts (PDX) are tumor-in-mouse models for cancer. PDX collections, such as the NCI PDXNet, are powerful resources for preclinical therapeutic testing. However, variations in experimental and analysis procedures have limited interpretability. To determine the robustness of PDX studies, the PDXNet tested temozolomide drug response for three prevalidated PDX models (sensitive, resistant, and intermediate) across four blinded PDX Development and Trial Centers using independently selected standard operating procedures. Each PDTC was able to correctly identify the sensitive, resistant, and intermediate models, and statistical evaluations were concordant across all groups. We also developed and benchmarked optimized PDX informatics pipelines, and these yielded robust assessme

SUBMITTER: Evrard YA 

PROVIDER: S-EPMC7272270 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature